• 1
  • 2
  • 3
  • 4
  • 2
  • 2
Schedule a meeting
Welcome To ProWin Consultants

ProWin Consultants was conceived and set up by Mr.Praveen R K along with Mrs. Deepa Praveen. Mr. Praveen R K is a Certified Financial Planner ( CFP) after his two decades of Financial Services Industry experience. He worked with companies like Sriram Group, HDFC, Cigna TTK at various Managerial roles. He strongly believes that quality financial planning is no longer an option, but a necessity for all people across the society. He is ably supported by Mrs. Deepa Praveen, who is a Science Graduate with an HR stint at one of the reputed Medical Colleges in Karnataka. She takes care of distribution and back -end operations at ProWin Consultants. She is also passionate about Fashion Designing.Read More

  • MF News
  • Market News
  • IPO News
  • Latest News

Amandeep Chopra Investors have taken comfort from the government's focus on inflation. The long-term yields have come off, said Amandeep Chopra of UTI MF, adding that the theme has to be sustained for a longer time.
Thu, 23 Jun 2016 10:35:08 +0530

Rossari Biotech#39;s Rs 496-crore IPO subscribed 79 times so far on last day The public issue consists of a fresh issue of Rs 50 crore and an offer for sale of 1.05 crore equity shares by its promoters Edward Menezes and Sunil Chari.
Wed, 15 Jul 2020 11:58:45 +0530

Rossari Biotech IPO subscribed 3 times on Day 2 amid retail, QIB interest In past 3 years (FY17-FY20), company has delivered stupendous growth on revenue, EBITDA and net profit level, which grew at a CAGR of 42 percent, 57 percent and 60 percent respectively.
Tue, 14 Jul 2020 14:40:37 +0530

Subscribe to Rossari Biotech: Emkay Global Financial Emkay Global Financial Rossari Biotech is planning to raise ~Rs4.95bn through a mix of fresh issue (Rs500mn, 1.17mn shares) combined with Offer for Sale (OFS) route (~Rs4.45bn, 10.5mn shares), to the public.
Mon, 13 Jul 2020 18:07:11 +0530

Subscribe to Rossari Biotech: Motilal Oswal Motilal Oswal Hence, investors can Subscribe the IPO from a long term perspective.
Mon, 13 Jul 2020 17:47:49 +0530

Subscribe to Rossari Biotech: Ventura Securities Ventura Securities Rossari Biotech (Rossari) is one of the leading specialty chemicals manufacturing company in India, catering to various customer needs across FMCG, apparel, and poultry and animal feed industries.
Mon, 13 Jul 2020 17:31:48 +0530

Subscribe to Rossari Biotech: Mehta Equities Mehta Equities has come out with its report on Rossari Biotech. The research firm has recommended to "Subscribe#39;#39; the IPO in its research report as on July 10, 2020
Mon, 13 Jul 2020 17:16:34 +0530

Subscribe to Rossari Biotech: Arihant Capital Arihant Capital has come out with its report on Rossari Biotech. The research firm has recommended to "Subscribe#39;#39; the IPO in its research report as on July 10, 2020
Mon, 13 Jul 2020 17:14:27 +0530

Subscribe to Rossari Biotech: Hem Securities Hem Securities has come out with its report on Rossari Biotech. The research firm has recommended to "Subscribe#39;#39; the IPO in its research report as on July 10, 2020
Mon, 13 Jul 2020 17:13:06 +0530

Subscribe to Rossari Biotech: Anand Rathi Anand Rathi has come out with its report on Rossari Biotech. The research firm has recommended to "Subscribe#39;#39; the IPO in its research report as on July 10, 2020
Mon, 13 Jul 2020 17:11:06 +0530

Subscribe to Rossari Biotech: Choice Equity Broking Choice Equity Broking has come out with its report on Rossari Biotech. The research firm has recommended to "Subscribe#39;#39; the IPO in its research report as on July 10, 2020
Mon, 13 Jul 2020 16:55:18 +0530

Ideas for Profit | Rossari Biotech IPO opens for subscription today; should you subscribe? The company already garnered Rs 149 crore through its anchor book on July 10 and has been subscribed 8 percent so far on July 13, day one of bidding
Mon, 13 Jul 2020 14:27:38 +0530

Subscribe to Rossari Biotech: Geojit Geojit Rossari Biotech Limited (RB) is one of the leading manufacturer of specialty chemicals in India with a diversified product profile of 2,030 products.
Mon, 13 Jul 2020 13:23:36 +0530

Subscribe to Rossari Biotech: Angel Broking Angel Broking At the upper end of the price band, Rossari demands PE multiple of 32.1x F.Y.20 fully diluted EPS.
Mon, 13 Jul 2020 13:15:07 +0530

Subscribe to Rossari Biotech: Way2Wealth Way2Wealth Company was initially incorporated as “Rossari Labtech” on March 6, 2003, as a partnership firm however subsequently was changed into company and named Rossari Biotech Ltd on 5th December 2003.
Mon, 13 Jul 2020 13:09:25 +0530

Rossari Biotech IPO opens today, subscribed 60% on Day 1 After a lull in the IPO market since SBI Card issue, Rossari Biotech is inaugurating the IPO season with its Rs 496 crore fresh issue and OFS
Mon, 13 Jul 2020 11:35:03 +0530

Rajesh Kothari The long-term India story still remains intact although in the short-term there could be some impact due to demonetisation, adding that over the longer term India would be a more structurally stronger story, said Rajesh Kothari, Managing Director, Alfaccurate Advisors.
Fri, 25 Nov 2016 12:37:33 +0530

Porinju Veliyath Over two weeks afterdemonetisation drive commenced, Porinju Veliyath — Managing Director and Portfolio Manager at Equity Intelligence India — continues to remain upbeat about markets. Veliyath said that he expects the market to gain going forward and large money can be made in midcaps and small caps.
Fri, 25 Nov 2016 12:00:16 +0530

Ashwani Gujral The market will bottom out very soon, says Mitesh Thacker of mitechthacker.com. Once the private banks bottom out, the market would be at its lowest considering the fundamentals. This would be a great time to buy into the market.
Thu, 24 Nov 2016 17:25:25 +0530

Ajay Srivastava Ajay Srivastava of Dimensions Consulting told CNBC-TV18 that the economy is likely to contract for next few quarters and political agenda will rule the global markets.
Thu, 24 Nov 2016 15:15:33 +0530

Sanjay Dutt The risk-reward ratio in the market looks reasonably favourable right now, says Sanjay Dutt of Quantum AMC. He feels there is no reason to panic and instead advises picking up quality stocks.
Thu, 24 Nov 2016 14:37:48 +0530

Nilesh Shetty Speaking to CNBC-TV18 Nilesh Shetty of Quantum AMC said that the forecast for the second half of the fiscal year has always been positive. However reality has always proved it wrong.
Thu, 24 Nov 2016 12:26:23 +0530

Surendra Goyal Surendra Goyal said that this depreciation in rupee will spook foreign institutional investors (FIIs).
Thu, 24 Nov 2016 10:43:56 +0530

Saurabh Handa The government’s currency overhaul, or demonetisation drive, is unlike to impact oil and gas businesses in the near term as fuel demand look good, according to Citi Group. Saurabh Handa, oil and gas analyst at Citi Group said that he is quite positive on the sector and stock valuations are reasonable.
Thu, 24 Nov 2016 10:10:13 +0530

Ashwani Gujral The 50-share Nifty should consolidate between 7,920 - 8,100 for a few weeks, according to Mitesh Thacker of miteshthacker.com.
Wed, 23 Nov 2016 20:08:13 +0530

Saurabh Mukherjea Speaking to CNBC-TV18 Saurabh Mukherjea of Ambit Capital said that we have been accused of saying a lot of things that are thought of as sensational but facts and subsequent events have borne them out.
Wed, 23 Nov 2016 09:42:44 +0530

Ashwani Gujral Ambareesh Baliga, a market expert says for the long-term investor, the current market condition is a great buying opportinity. The market, after about 2-3 months of uncertainty, is bound to do well.
Tue, 22 Nov 2016 15:36:14 +0530

Abhay Laijawala Speaking to CNBC-TV18, Abhay Laijawala said the there will be a transition from monetary policy to fiscal policy for which the market is not prepared and expects the market to remain volatile with a downward bias for the near term.
Tue, 22 Nov 2016 11:33:55 +0530

Demonetisation to be good for inflation, bond yields, INR: IDFC Anish Damania of IDFC says demonetisation is expected to be positive for inflation, bond yields and rupee, but it would have a negative impact on GDP and money supply.
Tue, 22 Nov 2016 10:42:39 +0530

Vivek Rajpal Watch the interview of Vivek Rajpal, Rates Strategist at Nomura India with Latha Venkatesh, Sonia Shenoy and Anuj Singhal on CNBC-TV18. He shared his views about the money market.
Tue, 22 Nov 2016 10:13:00 +0530

Govindarajan Chellappa In an interview with CNBC-TV18, Chellappa says financial services and consumer discretionary segments like auto be the worst hit as the currency move will hurt consumer sentiment as well as the wealth effect.
Tue, 22 Nov 2016 10:11:49 +0530

Market Watch
Copyright © 2017 ProWin Consultants - All Rights Reserved | Powered By : RED Vision Technologies